Forecasting Clinical Dose–Response From Preclinical Studies in Tuberculosis Research: Translational Predictions With Rifampicin. Issue 6 (19th June 2018)

• Record Type: Journal Article
• Authors: Wicha, Sebastian G.; Clewe, Oskar; Svensson, Robin J.; Gillespie, Stephen H.; Hu, Yanmin; Coates, Anthony R.M.; Simonsson, Ulrika S.H.
• Is Part Of: Clinical pharmacology & therapeutics. Volume 104:Issue 6(2018)
• Page Start: 1208
• Page End: 1218
• Publication Date: 2018-06-19
• Subjects: Pharmacology -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1002/cpt.1102
• Languages: English
• ISSNs: 0009-9236

Abstract

Abstract : A crucial step for accelerating tuberculosis drug development is bridging the gap between preclinical and clinical trials. In this study, we developed a preclinical model‐informed translational approach to predict drug effects across preclinical systems and early clinical trials using the in vitro ‐based Multistate Tuberculosis Pharmacometric (MTP) model using rifampicin as an example. The MTP model predicted rifampicin biomarker response observed in 1) a hollow‐fiber infection model, 2) a murine study to determine pharmacokinetic/pharmacodynamic indices, and 3) several clinical phase IIa early bactericidal activity (EBA) studies. In addition, we predicted rifampicin biomarker response at high doses of up to 50 mg/kg, leading to an increased median EBA0‐2 days (90% prediction interval) of 0.513 log CFU/mL/day (0.310; 0.701) compared to the standard dose of 10 mg/kg of 0.181 log/CFU/mL/day (0.076; 0.483). These results suggest that the translational approach could assist in the selection of drugs and doses in early‐phase clinical tuberculosis trials.